{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T17:02:29Z","timestamp":1789491749958,"version":"build-2803163510"},"reference-count":203,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T00:00:00Z","timestamp":1789430400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>Thrombotic thrombocytopenic purpura (TTP) is a rare and rapidly life-threatening thrombotic microangiopathy. Disseminated microvascular thrombosis and resulting ischemia are the critical events determining outcome, if left untreated. The pathogenic hallmark is a severe deficiency of the plasma metalloprotease ADAMTS13, resulting in impaired cleavage of ultra-large von Willebrand factor (vWF) multimers leading to platelet aggregation. The vast majority of TTP cases are acquired and immune-mediated, depleting ADAMTS13 through autoantibodies. In contrast, congenital deficiency of ADAMTS13 affects a minority of patients. Measurement of ADAMTS13 activity is the cornerstone for diagnosis and implementation of treatment. However, clinical prediction scores support early therapeutic decision-making when results are pending. Plasma exchange, immunosuppression and more recently, the anti-vWF nanobody caplacizumab, are the central pillars for treatment of immune-mediated TTP. Caplacizumab prevents microvascular thrombosis during the acute episode but does not address the autoimmune-mediated ADAMTS13 depletion, underscoring the importance of plasma exchange and immunosuppression. Congenital TTP was previously treated using ADAMTS13 replacement through regular plasma infusions, but provision of recombinant ADAMTS13 has recently transformed treatment in these patients. Despite major advances, relapse remains a persistent threat for patients, making structured, long-term follow-up necessary. Diagnostic advances may help improve relapse prediction and corresponding therapeutic management. This review summarizes current concepts in the pathophysiology, diagnosis, clinical management of TTP and highlights recent therapeutic advancements and future challenges.<\/jats:p>","DOI":"10.3389\/fmed.2026.1806030","type":"journal-article","created":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T16:05:16Z","timestamp":1789488316000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Current standards and novel concepts in thrombotic thrombocytopenic purpura"],"prefix":"10.3389","volume":"13","author":[{"given":"Johannes","family":"Bloehdorn","sequence":"first","affiliation":[{"name":"Department of Hematology, Oncology, Infectious Disease and Palliative Care Medicine, Alb-Fils Klinikum GmbH","place":["G\u00f6ppingen, Germany"]},{"name":"School of Cancer Sciences, Faculty of Medicine, Centre for Cancer Immunology, University of Southampton","place":["Southampton, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark S.","family":"Cragg","sequence":"additional","affiliation":[{"name":"School of Cancer Sciences, Faculty of Medicine, Centre for Cancer Immunology, University of Southampton","place":["Southampton, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Bommer","sequence":"additional","affiliation":[{"name":"Department of Hematology, Oncology, Infectious Disease and Palliative Care Medicine, Alb-Fils Klinikum GmbH","place":["G\u00f6ppingen, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"103168","DOI":"10.1016\/j.eclinm.2025.103168","article-title":"Caplacizumab use in immune-mediated thrombotic thrombocytopenic purpura: an international multicentre retrospective Cohort study (The Capla 1000+ project).","volume":"82","author":"Coppo","year":"2025","journal-title":"EClinicalMedicine."},{"key":"B2","doi-asserted-by":"publisher","first-page":"17020","DOI":"10.1038\/nrdp.2017.20","article-title":"Thrombotic thrombocytopenic purpura.","volume":"3","author":"Kremer Hovinga","year":"2017","journal-title":"Nat Rev Dis Primers."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.3324\/haematol.2025.287535","article-title":"The third form of thrombotic thrombocytopenic purpura shows up again: what is it, does it even exist, how to find out? Comment on \u201cAcquired thrombotic thrombocytopenic purpura without detectable anti-ADAMTS13 antibodies: a possible underlying autoimmune mechanism\u201d and on \u201cThe different faces of thrombotic thrombocytopenic purpura.\u201d.","volume":"110","author":"Lammle","year":"2025","journal-title":"Haematologica"},{"key":"B4","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1182\/blood.2022017023","article-title":"Long-term risk of relapse in immune-mediated thrombotic thrombocytopenic purpura and the role of anti-CD20 therapy.","volume":"141","author":"Doyle","year":"2023","journal-title":"Blood."},{"key":"B5","doi-asserted-by":"publisher","first-page":"363","DOI":"10.2147\/JBM.S464365","article-title":"A systematic review of the epidemiology and disease burden of congenital and immune-mediated thrombotic thrombocytopenic purpura.","volume":"15","author":"Du","year":"2024","journal-title":"J Blood Med."},{"key":"B6","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1186\/s13023-022-02409-3","article-title":"Incidence of thrombotic microangiopathies in Quebec: insight from a laboratory centralizing ADAMTS-13 testing.","volume":"17","author":"Merlen","year":"2022","journal-title":"Orphanet J Rare Dis."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1002\/pbc.24612","article-title":"Children and adults with thrombotic thrombocytopenic purpura associated with severe, acquired Adamts13 deficiency: comparison of incidence, demographic and clinical features.","volume":"60","author":"Reese","year":"2013","journal-title":"Pediatric Blood Cancer."},{"key":"B8","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1186\/s13023-019-1240-0","article-title":"Incidence of acquired thrombotic thrombocytopenic purpura in Germany: a hospital level study.","volume":"14","author":"Miesbach","year":"2019","journal-title":"Orphanet J Rare Dis."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1056\/NEJMra1813013","article-title":"Hereditary Thrombotic Thrombocytopenic Purpura.","volume":"381","author":"Kremer Hovinga","year":"2019","journal-title":"New Engl J Med."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1111\/j.1538-7836.2011.04399.x","article-title":"Polymorphisms and mutations of ADAMTS13 in the Japanese population and estimation of the number of patients with Upshaw\u2013Schulman syndrome.","volume":"9","author":"Kokame","year":"2011","journal-title":"J Thrombosis Haemostasis."},{"key":"B11","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1111\/jth.13186","article-title":"High prevalence of hereditary thrombotic thrombocytopenic purpura in central Norway: from clinical observation to evidence.","volume":"14","author":"von Krogh","year":"2016","journal-title":"J Thrombosis Haemostasis."},{"key":"B12","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s12863-021-01010-0","article-title":"The global carrier frequency and genetic prevalence of Upshaw-Schulman syndrome.","volume":"22","author":"Zhao","year":"2021","journal-title":"BMC Genomic Data."},{"key":"B13","doi-asserted-by":"publisher","first-page":"4386","DOI":"10.1182\/bloodadvances.2024013421","article-title":"Global prevalence of hereditary thrombotic thrombocytopenic purpura determined by genetic analysis.","volume":"8","author":"Seidizadeh","year":"2024","journal-title":"Blood Adv."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1792","DOI":"10.1111\/j.1538-7836.2012.04852.x","article-title":"A phenotype\u2013genotype correlation of ADAMTS13 mutations in congenital thrombotic thrombocytopenic purpura patients treated in the United Kingdom.","volume":"10","author":"Camilleri","year":"2012","journal-title":"J Thrombosis Haemostasis."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.1182\/blood-2018-11-884700","article-title":"Characterization and treatment of congenital thrombotic thrombocytopenic purpura.","volume":"133","author":"Alwan","year":"2019","journal-title":"Blood."},{"key":"B16","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1111\/ejh.13107","article-title":"Pediatric thrombotic thrombocytopenic purpura.","volume":"101","author":"Joly","year":"2018","journal-title":"Eur J Haematol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1182\/blood-2020-134394","article-title":"Frequency and severity of pregnancy complications in women with hereditary thrombotic thrombocytopenic purpura.","volume":"136","author":"Kasht","year":"2020","journal-title":"Blood."},{"key":"B18","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1182\/blood-2014-06-528406","article-title":"von Willebrand factor biosynthesis, secretion, and clearance: connecting the far ends.","volume":"125","author":"Lenting","year":"2015","journal-title":"Blood."},{"key":"B19","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1182\/blood-2005-01-0152","article-title":"Localization of ADAMTS13 to the stellate cells of human liver.","volume":"106","author":"Uemura","year":"2005","journal-title":"Blood."},{"key":"B20","doi-asserted-by":"publisher","first-page":"7899","DOI":"10.1073\/pnas.0608422104","article-title":"Shear-induced unfolding triggers adhesion of von Willebrand factor fibers.","volume":"104","author":"Schneider","year":"2007","journal-title":"Proc Natl Acad Sci U S A."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1126\/science.1170905","article-title":"Mechanoenzymatic cleavage of the ultralarge vascular protein von willebrand factor.","volume":"324","author":"Zhang","year":"2009","journal-title":"Science."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1182\/blood-2017-04-636431","article-title":"Pathophysiology of thrombotic thrombocytopenic purpura.","volume":"130","author":"Sadler","year":"2017","journal-title":"Blood."},{"key":"B23","doi-asserted-by":"publisher","first-page":"2143","DOI":"10.1182\/blood-2018-04-840090","article-title":"Preemptive rituximab prevents long-term relapses in immune-mediated thrombotic thrombocytopenic purpura.","volume":"132","author":"Jestin","year":"2018","journal-title":"Blood."},{"key":"B24","doi-asserted-by":"publisher","first-page":"2175","DOI":"10.1182\/blood-2016-06-724161","article-title":"Clinical importance of ADAMTS13 activity during remission in patients with acquired thrombotic thrombocytopenic purpura.","volume":"128","author":"Page","year":"2016","journal-title":"Blood."},{"key":"B25","doi-asserted-by":"publisher","first-page":"e01256","DOI":"10.1016\/j.idcr.2021.e01256","article-title":"COVID-19 infection triggering thrombotic thrombocytopenic purpura.","volume":"26","author":"Alhomoud","year":"2021","journal-title":"IDCases."},{"key":"B26","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1007\/s00277-022-04936-2","article-title":"Maternal and fetal outcomes of pregnancy occurring after a diagnosis of immune-mediated thrombotic thrombocytopenic purpura.","volume":"101","author":"Brown","year":"2022","journal-title":"Ann Hematol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"689","DOI":"10.2169\/internalmedicine.49.2957","article-title":"Influenza a infection triggers thrombotic thrombocytopenic purpura by producing the Anti-ADAMTS13 IgG inhibitor.","volume":"49","author":"Kosugi","year":"2010","journal-title":"Intern Med."},{"key":"B28","doi-asserted-by":"publisher","first-page":"5888","DOI":"10.1182\/blood-2012-02-408914","article-title":"Unexpected frequency of Upshaw-Schulman syndrome in pregnancy-onset thrombotic thrombocytopenic purpura.","volume":"119","author":"Moatti-Cohen","year":"2012","journal-title":"Blood."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1160\/TH13-08-0713","article-title":"The impact of congenital thrombotic thrombocytopenic purpura on pregnancy complications.","volume":"111","author":"von Krogh","year":"2014","journal-title":"Thrombosis Haemostasis."},{"key":"B30","doi-asserted-by":"publisher","first-page":"3379","DOI":"10.3390\/jcm9103379","article-title":"The HLA variant rs6903608 is associated with disease onset and relapse of immune-mediated thrombotic thrombocytopenic purpura in caucasians.","volume":"9","author":"Mancini","year":"2020","journal-title":"J Clin Med."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1111\/j.1538-7836.2009.03568.x","article-title":"IgG subclass distribution of anti-ADAMTS13 antibodies in patients with acquired thrombotic thrombocytopenic purpura.","volume":"7","author":"Ferrari","year":"2009","journal-title":"J Thrombosis Haemostasis."},{"key":"B32","doi-asserted-by":"publisher","first-page":"2993","DOI":"10.1182\/blood.2022019252","article-title":"Mechanisms of inhibition of human monoclonal antibodies in immune thrombotic thrombocytopenic purpura.","volume":"141","author":"Halkidis","year":"2023","journal-title":"Blood."},{"key":"B33","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1111\/jth.15822","article-title":"ADAMTS13 conformations and mechanism of inhibition in immune thrombotic thrombocytopenic purpura.","volume":"20","author":"Halkidis","year":"2022","journal-title":"J Thrombosis Haemostasis."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1056\/NEJM199811263392203","article-title":"Antibodies to von willebrand factor\u2013cleaving protease in acute thrombotic thrombocytopenic purpura.","volume":"339","author":"Tsai","year":"1998","journal-title":"New Engl J Med."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.1111\/j.1538-7836.2012.04808.x","article-title":"ADAMTS-13 activity and autoantibodies classes and subclasses as prognostic predictors in acquired thrombotic thrombocytopenic purpura.","volume":"10","author":"Bettoni","year":"2012","journal-title":"J Thrombosis Haemostasis."},{"key":"B36","doi-asserted-by":"publisher","first-page":"2815","DOI":"10.1182\/blood-2006-02-006064","article-title":"Prognostic value of anti-ADAMTS13 antibody features (Ig isotype, titer, and inhibitory effect) in a cohort of 35 adult French patients undergoing a first episode of thrombotic microangiopathy with undetectable ADAMTS13 activity.","volume":"109","author":"Ferrari","year":"2007","journal-title":"Blood."},{"key":"B37","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1186\/s12879-019-4037-9","article-title":"Cytomegalovirus induced refractory TTP in an immunocompetent individual: a case report.","volume":"19","author":"Boteju","year":"2019","journal-title":"BMC Infect Dis."},{"key":"B38","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1016\/j.mehy.2005.06.015","article-title":"Thrombotic thrombocytopenic purpura: proposal of a new pathogenic mechanism involving Helicobacter pylori infection.","volume":"65","author":"Franchini","year":"2005","journal-title":"Med Hypotheses."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.1111\/j.1537-2995.2007.01346.x","article-title":"ADAMTS13 activity and the presence of acquired inhibitors in human immunodeficiency virus\u2013related thrombotic thrombocytopenic purpura.","volume":"47","author":"Gunther","year":"2007","journal-title":"Transfusion."},{"key":"B40","doi-asserted-by":"publisher","first-page":"e180","DOI":"10.1097\/MJT.0b013e3181d1b4a1","article-title":"A case of severe thrombotic thrombocytopenic purpura with concomitant legionella pneumonia: review of pathogenesis and treatment.","volume":"18","author":"Talebi","year":"2011","journal-title":"Am J Therapeut."},{"key":"B41","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.blre.2014.07.004","article-title":"Acquired TTP: ADAMTS13 meets the immune system.","volume":"28","author":"Verbij","year":"2014","journal-title":"Blood Rev."},{"key":"B42","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/j.jhep.2004.08.030","article-title":"Development of ADAMTS13 inhibitor in a patient with hepatitis C virus-related liver cirrhosis causes thrombotic thrombocytopenic purpura.","volume":"42","author":"Yagita","year":"2005","journal-title":"J Hepatol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1016\/j.ebiom.2015.06.007","article-title":"Pathogenicity of anti-ADAMTS13 autoantibodies in acquired thrombotic thrombocytopenic purpura.","volume":"2","author":"Thomas","year":"2015","journal-title":"EBioMedicine."},{"key":"B44","doi-asserted-by":"publisher","first-page":"3427","DOI":"10.1182\/bloodadvances.2020004172","article-title":"Anti-ADAMTS13 autoantibody profiling in patients with immune-mediated thrombotic thrombocytopenic purpura.","volume":"5","author":"Kangro","year":"2021","journal-title":"Blood Adv."},{"key":"B45","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1182\/bloodadvances.2022008885","article-title":"ADAMTS13 conformation and immunoprofiles in Japanese patients with immune-mediated thrombotic thrombocytopenic purpura.","volume":"7","author":"Sakai","year":"2023","journal-title":"Blood Adv."},{"key":"B46","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.thromres.2011.03.010","article-title":"Epitope analysis of autoantibodies to ADAMTS13 in patients with acquired thrombotic thrombocytopenic purpura.","volume":"128","author":"Yamaguchi","year":"2011","journal-title":"Thrombosis Res."},{"key":"B47","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.3324\/haematol.2009.019299","article-title":"Multiple domains of ADAMTS13 are targeted by autoantibodies against ADAMTS13 in patients with acquired idiopathic thrombotic thrombocytopenic purpura.","volume":"95","author":"Zheng","year":"2010","journal-title":"Haematologica."},{"key":"B48","doi-asserted-by":"publisher","first-page":"18578","DOI":"10.1073\/pnas.1411979112","article-title":"Conformational activation of ADAMTS13.","volume":"111","author":"South","year":"2014","journal-title":"Proc Natl Acad Sci U S A."},{"key":"B49","doi-asserted-by":"publisher","first-page":"18584","DOI":"10.1073\/pnas.1413282112","article-title":"Allosteric activation of ADAMTS13 by von Willebrand factor.","volume":"111","author":"Muia","year":"2014","journal-title":"Proc Natl Acad Sci U S A."},{"key":"B50","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1111\/jth.13922","article-title":"An open conformation of ADAMTS-13 is a hallmark of acute acquired thrombotic thrombocytopenic purpura.","volume":"16","author":"Roose","year":"2018","journal-title":"J Thrombosis Haemostasis."},{"key":"B51","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1182\/blood.2019004221","article-title":"Open ADAMTS13, induced by antibodies, is a biomarker for subclinical immune-mediated thrombotic thrombocytopenic purpura.","volume":"136","author":"Roose","year":"2020","journal-title":"Blood."},{"key":"B52","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1111\/trf.12912","article-title":"Absolute immature platelet count dynamics in diagnosing and monitoring the clinical course of thrombotic thrombocytopenic purpura.","volume":"55","author":"Hong","year":"2015","journal-title":"Transfusion."},{"key":"B53","doi-asserted-by":"publisher","first-page":"597734","DOI":"10.3389\/fmed.2020.597734","article-title":"Immature platelet dynamics in immune-mediated thrombocytopenic states.","volume":"7","author":"Reeves","year":"2020","journal-title":"Front Med."},{"key":"B54","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.thromres.2020.11.028","article-title":"Immature platelet dynamics correlate with ADAMTS13 deficiency and predict therapy response in immune-mediated thrombotic thrombocytopenic purpura.","volume":"198","author":"Zhu","year":"2021","journal-title":"Thrombosis Res."},{"key":"B55","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.thromres.2019.05.011","article-title":"Absolute immature platelet count dynamics of thrombotic thrombocytopenic purpura patients with high ADAMTS13 inhibitor.","volume":"179","author":"Gokozan","year":"2019","journal-title":"Thrombosis Res."},{"key":"B56","doi-asserted-by":"publisher","first-page":"4002","DOI":"10.1182\/blood-2024-207991","article-title":"Mutation analysis of the ADAMTS13 gene in patients with congenital thrombotic thrombocytopenic purpura from the rADAMTS13 Phase 3 study.","volume":"144","author":"Diogo","year":"2024","journal-title":"Blood."},{"key":"B57","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1111\/j.1538-7836.2011.04341.x","article-title":"Natural history of upshaw\u2013schulman syndrome based on ADAMTS13 gene analysis in Japan.","volume":"9","author":"Fujimura","year":"2011","journal-title":"J Thrombosis Haemostasis."},{"key":"B58","doi-asserted-by":"publisher","first-page":"2836","DOI":"10.1182\/blood-2016-10-709857","article-title":"Thrombotic thrombocytopenic purpura.","volume":"129","author":"Joly","year":"2017","journal-title":"Blood."},{"key":"B59","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1111\/jth.13956","article-title":"Pathophysiology of thrombotic thrombocytopenic purpura and hemolytic uremic syndrome.","volume":"16","author":"Kremer Hovinga","year":"2018","journal-title":"J Thrombosis Haemostasis."},{"key":"B60","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1038\/35097008","article-title":"Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura.","volume":"413","author":"Levy","year":"2001","journal-title":"Nature."},{"key":"B61","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1002\/humu.21143","article-title":"ADAMTS13 mutations and polymorphisms in congenital thrombotic thrombocytopenic purpura.","volume":"31","author":"Lotta","year":"2010","journal-title":"Hum Mutat."},{"key":"B62","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1182\/blood-2012-01-403113","article-title":"Residual plasmatic activity of ADAMTS13 is correlated with phenotype severity in congenital thrombotic thrombocytopenic purpura.","volume":"120","author":"Lotta","year":"2012","journal-title":"Blood."},{"key":"B63","doi-asserted-by":"publisher","first-page":"2107","DOI":"10.3324\/haematol.2019.216796","article-title":"The international hereditary thrombotic thrombocytopenic purpura registry: key findings at enrollment until 2017.","volume":"104","author":"van Dorland","year":"2019","journal-title":"Haematologica."},{"key":"B64","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1111\/j.1538-7836.2008.02846.x","article-title":"Prevalence of the ADAMTS-13 missense mutation R1060W in late onset adult thrombotic thrombocytopenic purpura.","volume":"6","author":"Camilleri","year":"2008","journal-title":"J Thrombosis Haemostasis."},{"key":"B65","doi-asserted-by":"publisher","first-page":"1902","DOI":"10.1055\/s-0038-1673686","article-title":"ADAMTS13 gene mutations influence ADAMTS13 conformation and disease age-onset in the french cohort of upshaw\u2013schulman syndrome.","volume":"118","author":"Joly","year":"2018","journal-title":"Thrombosis Haemostasis."},{"key":"B66","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1160\/TH05-12-0817","article-title":"A common origin of the 4143insA ADAMTS13 mutation.","volume":"96","author":"Schneppenheim","year":"2006","journal-title":"Thrombosis Haemostasis."},{"key":"B67","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1182\/blood-2014-02-553131","article-title":"Thrombotic thrombocytopenic purpura and pregnancy: presentation, management, and subsequent pregnancy outcomes.","volume":"124","author":"Scully","year":"2014","journal-title":"Blood."},{"key":"B68","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1111\/j.1365-2141.2008.07515.x","article-title":"Pregnancy-induced thrombocytopenia and TTP, and the risk of fetal death, in Upshaw\u2013Schulman syndrome: a series of 15 pregnancies in 9 genotyped patients.","volume":"144","author":"Fujimura","year":"2009","journal-title":"Br J Haematol."},{"key":"B69","doi-asserted-by":"publisher","first-page":"8137","DOI":"10.3390\/ijms25158137","article-title":"ADAMTS13 in the new era of TTP.","volume":"25","author":"Papakonstantinou","year":"2024","journal-title":"Intern J Mol Sci."},{"key":"B70","doi-asserted-by":"publisher","first-page":"638","DOI":"10.3324\/haematol.2022.280768","article-title":"ADAMTS13 conformation is closed in non-immune acquired thrombotic thrombocytopenic purpura of unidentified pathophysiology.","volume":"108","author":"Joly","year":"2023","journal-title":"Haematologica."},{"key":"B71","doi-asserted-by":"publisher","first-page":"e237","DOI":"10.1016\/S2352-3026(16)30018-7","article-title":"Epidemiology and pathophysiology of adulthood-onset thrombotic microangiopathy with severe ADAMTS13 deficiency (thrombotic thrombocytopenic purpura): a cross-sectional analysis of the French national registry for thrombotic microangiopathy.","volume":"3","author":"Mariotte","year":"2016","journal-title":"Lancet Haematol."},{"key":"B72","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1182\/blood-2004-03-1101","article-title":"Proteolytic inactivation of ADAMTS13 by thrombin and plasmin.","volume":"105","author":"Crawley","year":"2005","journal-title":"Blood."},{"key":"B73","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1160\/TH08-01-0006","article-title":"Comprehensive analysis of ADAMTS13 in patients with liver cirrhosis.","volume":"99","author":"Uemura","year":"2008","journal-title":"Thrombosis Haemostasis."},{"key":"B74","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.3324\/haematol.2024.285391","article-title":"Acquired thrombotic thrombocytopenic purpura without detectable anti-ADAMTS13 antibodies: a possible underlying autoimmune mechanism.","volume":"110","author":"Simon","year":"2025","journal-title":"Haematologica."},{"key":"B75","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1182\/blood.2020009150","article-title":"Redefining outcomes in immune TTP: an international working group consensus report.","volume":"137","author":"Cuker","year":"2021","journal-title":"Blood."},{"key":"B76","doi-asserted-by":"publisher","first-page":"4060","DOI":"10.1182\/blood-2010-07-271445","article-title":"How I treat patients with thrombotic thrombocytopenic purpura: 2010.","volume":"116","author":"George","year":"2010","journal-title":"Blood."},{"key":"B77","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1182\/bloodadvances.2017005124","article-title":"Thrombotic thrombocytopenic purpura: diagnostic criteria, clinical features, and long-term outcomes from 1995 through 2015.","volume":"1","author":"Page","year":"2017","journal-title":"Blood Adv."},{"key":"B78","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1111\/bjh.19026","article-title":"A British Society for Haematology Guideline: diagnosis and management of thrombotic thrombocytopenic purpura and thrombotic microangiopathies.","volume":"203","author":"Scully","year":"2023","journal-title":"Br J Haematol."},{"key":"B79","doi-asserted-by":"publisher","first-page":"e931","DOI":"10.1097\/CCM.0000000000005164","article-title":"Pattern of brain injury in patients with thrombotic thrombocytopenic purpura in the precaplacizumab era.","volume":"49","author":"Mirouse","year":"2021","journal-title":"Crit Care Med."},{"key":"B80","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1212\/WNL.0b013e3181aaea1b","article-title":"Brain lesions are most often reversible in acute thrombotic thrombocytopenic purpura.","volume":"73","author":"Burrus","year":"2009","journal-title":"Neurology."},{"key":"B81","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1111\/jth.12826","article-title":"Acute renal failure is prevalent in patients with thrombotic thrombocytopenic purpura associated with low plasma ADAMTS13 activity.","volume":"13","author":"Zafrani","year":"2015","journal-title":"J Thrombosis Haemostasis."},{"key":"B82","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1111\/jth.12790","article-title":"Cardiac troponin-I on diagnosis predicts early death and refractoriness in acquired thrombotic thrombocytopenic purpura. experience of the french thrombotic microangiopathies reference center.","volume":"13","author":"Benhamou","year":"2015","journal-title":"J Thrombosis Haemostasis."},{"key":"B83","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1111\/j.1538-7836.2009.03285.x","article-title":"Cardiac involvement in acute thrombotic thrombocytopenic purpura: association with troponin T and IgG antibodies to ADAMTS 13.","volume":"7","author":"Hughes","year":"2009","journal-title":"J Thrombosis Haemostasis."},{"key":"B84","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1159\/000544724","article-title":"Microangiopathic anemia.","volume":"52","author":"Bommer","year":"2025","journal-title":"Transfus Med Hemotherapy."},{"key":"B85","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1182\/asheducation-2018.1.530","article-title":"Clinical and laboratory diagnosis of TTP: an integrated approach.","volume":"2018","author":"Chiasakul","year":"2018","journal-title":"Hematology."},{"key":"B86","doi-asserted-by":"publisher","first-page":"3711","DOI":"10.1016\/j.jtha.2025.06.002","article-title":"2025 focused update of the 2020 ISTH guidelines for management of thrombotic thrombocytopenic purpura.","volume":"23","author":"Zheng","year":"2025","journal-title":"J Thrombosis Haemostasis."},{"key":"B87","doi-asserted-by":"publisher","first-page":"e10208","DOI":"10.1371\/journal.pone.0010208","article-title":"Predictive features of severe acquired ADAMTS13 deficiency in idiopathic thrombotic microangiopathies: the French TMA reference center experience.","volume":"5","author":"Coppo","year":"2010","journal-title":"PLoS One"},{"key":"B88","doi-asserted-by":"publisher","first-page":"e157","DOI":"10.1016\/S2352-3026(17)30026-1","article-title":"Derivation and external validation of the PLASMIC score for rapid assessment of adults with thrombotic microangiopathies: a cohort study.","volume":"4","author":"Bendapudi","year":"2017","journal-title":"Lancet Haematol."},{"key":"B89","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1111\/j.1537-2995.2010.02653.x","article-title":"The utility of patient characteristics in predicting severe ADAMTS13 deficiency and response to plasma exchange.","volume":"50","author":"Bentley","year":"2010","journal-title":"Transfusion."},{"key":"B90","doi-asserted-by":"publisher","first-page":"485","DOI":"10.3343\/alm.2023.43.5.485","article-title":"Performance validation of three scoring systems for the prediction of thrombotic microangiopathy due to severe ADAMTS13 deficiency and the response to therapeutic plasma exchange: first study in Korea.","volume":"43","author":"Park","year":"2023","journal-title":"Ann Lab Med."},{"key":"B91","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1111\/trf.15954","article-title":"Diagnostic accuracy of the PLASMIC score in patients with suspected thrombotic thrombocytopenic purpura: a systematic review and meta-analysis.","volume":"60","author":"Paydary","year":"2020","journal-title":"Transfusion."},{"key":"B92","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1182\/hematology.2025000757","article-title":"Tailored treatment of acute immune-mediated thrombotic thrombocytopenic purpura.","volume":"2025","author":"V\u00f6lker","year":"2025","journal-title":"Hematology."},{"key":"B93","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.thromres.2022.05.008","article-title":"Comparison of absolute immature platelet count to the PLASMIC score at presentation in predicting ADAMTS13 deficiency in suspected thrombotic thrombocytopenic purpura.","volume":"215","author":"Reeves","year":"2022","journal-title":"Thrombosis Res."},{"key":"B94","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/S0140-6736(17)30062-4","article-title":"Haemolytic uraemic syndrome.","volume":"390","author":"Fakhouri","year":"2017","journal-title":"Lancet."},{"key":"B95","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1182\/blood.2022017860","article-title":"How I diagnose and treat atypical hemolytic uremic syndrome.","volume":"141","author":"Fakhouri","year":"2023","journal-title":"Blood."},{"key":"B96","doi-asserted-by":"publisher","first-page":"352","DOI":"10.3390\/diagnostics14040352","article-title":"HELLP syndrome and differential diagnosis with other thrombotic microangiopathies in pregnancy.","volume":"14","author":"Giannubilo","year":"2024","journal-title":"Diagnostics."},{"key":"B97","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1182\/blood.2020005221","article-title":"Management of thrombotic microangiopathy in pregnancy and postpartum: report from an international working group.","volume":"136","author":"Fakhouri","year":"2020","journal-title":"Blood."},{"key":"B98","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1055\/s-0036-1587683","article-title":"Thrombotic thrombocytopenic purpura and atypical hemolytic uremic syndrome microangiopathy in pregnancy.","volume":"42","author":"Scully","year":"2016","journal-title":"Sem Thrombosis Hemostasis."},{"key":"B99","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1182\/hematology.2024000544","article-title":"Catastrophic antiphospholipid syndrome: a CAPS-tivating hematologic disease.","volume":"2024","author":"Salter","year":"2024","journal-title":"Hematology."},{"key":"B100","doi-asserted-by":"publisher","first-page":"101081","DOI":"10.1016\/j.tranon.2021.101081","article-title":"Thrombotic microangiopathy in oncology \u2013 a review.","volume":"14","author":"Val\u00e9rio","year":"2021","journal-title":"Trans Oncol."},{"key":"B101","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1182\/blood-2014-11-611335","article-title":"Drug-induced thrombotic microangiopathy: a systematic review of published reports.","volume":"125","author":"Al-Nouri","year":"2015","journal-title":"Blood."},{"key":"B102","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1038\/s41409-024-02263-w","article-title":"Successful use of narsoplimab to treat allogeneic transplant-associated thrombotic microangiopathy while maintaining sirolimus.","volume":"59","author":"Alhomoud","year":"2024","journal-title":"Bone Marrow Trans."},{"key":"B103","doi-asserted-by":"publisher","first-page":"2447","DOI":"10.1200\/JCO.21.02389","article-title":"Narsoplimab, a mannan-binding lectin-associated serine Protease-2 inhibitor, for the treatment of adult hematopoietic stem-cell transplantation\u2013associated thrombotic microangiopathy.","volume":"40","author":"Khaled","year":"2022","journal-title":"J Clin Oncol."},{"key":"B104","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1200\/JOP.2016.012708","article-title":"Cancer and thrombotic microangiopathy.","volume":"12","author":"Scully","year":"2016","journal-title":"J Oncol Pract."},{"key":"B105","doi-asserted-by":"publisher","first-page":"2496","DOI":"10.1111\/jth.15010","article-title":"ISTH guidelines for treatment of thrombotic thrombocytopenic purpura.","volume":"18","author":"Zheng","year":"2020","journal-title":"J Thrombosis Haemostasis."},{"key":"B106","first-page":"219","article-title":"Exchange transfusions in the treatment of thrombotic thrombocytopenic purpura.","volume":"13","author":"Bukowski","year":"1976","journal-title":"Sem Hematol."},{"key":"B107","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1182\/blood.V50.3.413.413","article-title":"Plasmapheresis in the treatment of thrombotic thrombocytopenic purpura.","volume":"50","author":"Bukowski","year":"1977","journal-title":"Blood."},{"key":"B108","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.7326\/0003-4819-51-6-1409","article-title":"Unusual remission in a case of thrombotic thrombocytopenic purpura syndrome following fresh blood exchange transfusions.","volume":"51","author":"Rubinstein","year":"1959","journal-title":"Ann Intern Med."},{"key":"B109","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1056\/NEJM199108083250605","article-title":"Improved survival in thrombotic thrombocytopenic purpura\u2013hemolytic uremic syndrome.","volume":"325","author":"Bell","year":"1991","journal-title":"New Engl J Med."},{"key":"B110","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.thromres.2020.05.045","article-title":"Time from suspected thrombotic thrombocytopenic purpura to initiation of plasma exchange and impact on survival: a 10-year provincial retrospective cohort study.","volume":"193","author":"Sawler","year":"2020","journal-title":"Thrombosis Res."},{"key":"B111","doi-asserted-by":"publisher","first-page":"S17","DOI":"10.1007\/s00134-007-2875-1","article-title":"A comparison of complication rates based on published haemovigilance data.","volume":"33","author":"Flesland","year":"2007","journal-title":"Intens Care Med."},{"key":"B112","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1111\/j.1423-0410.1998.tb05478.x","article-title":"SD plasma in TTP and coagulation factor deficiencies for which no concentrates are available.","volume":"74","author":"Horowitz","year":"1998","journal-title":"Vox Sanguinis."},{"key":"B113","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1111\/trf.16777","article-title":"Evaluation of solvent\/detergent-treated plasma safety and efficacy in orthotopic liver transplant and thrombotic thrombocytopenic purpura patients: a single center experience.","volume":"62","author":"McRae","year":"2022","journal-title":"Transfusion."},{"key":"B114","doi-asserted-by":"publisher","first-page":"2445","DOI":"10.1111\/trf.13229","article-title":"Type of plasma preparation used for plasma exchange and clinical outcome of adult patients with acquired idiopathic thrombotic thrombocytopenic purpura: a French retrospective multicenter cohort study.","volume":"55","author":"Toussaint-Hacquard","year":"2015","journal-title":"Transfusion."},{"key":"B115","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1182\/asheducation-2014.1.444","article-title":"Thrombotic microangiopathy and indications for therapeutic plasma exchange.","volume":"2014","author":"Adamski","year":"2014","journal-title":"Hematology."},{"key":"B116","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1002\/(SICI)1098-1101(1998)13:3<133::AID-JCA7>3.0.CO;2-Z","article-title":"United States thrombotic thrombocytopenic purpura apheresis study group (US TTP ASG): multicenter survey and retrospective analysis of current efficacy of therapeutic plasma exchange.","volume":"13","author":"Bandarenko","year":"1998","journal-title":"J Clin Apheresis."},{"key":"B117","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1111\/trf.15901","article-title":"Therapeutic plasma exchange taper does not decrease exacerbations in immune thrombotic thrombocytopenic purpura patients.","volume":"60","author":"Raval","year":"2020","journal-title":"Transfusion."},{"key":"B118","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1056\/NEJMoa1505533","article-title":"Caplacizumab for acquired thrombotic thrombocytopenic purpura.","volume":"374","author":"Peyvandi","year":"2016","journal-title":"New Engl J Med."},{"key":"B119","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1056\/NEJMoa1806311","article-title":"Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura.","volume":"380","author":"Scully","year":"2019","journal-title":"New Engl J Med."},{"key":"B120","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1007\/s00277-009-0877-5","article-title":"High versus standard dose methylprednisolone in the acute phase of idiopathic thrombotic thrombocytopenic purpura: a randomized study.","volume":"89","author":"Balduini","year":"2010","journal-title":"Ann Hematol."},{"key":"B121","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1007\/s12185-020-02974-y","article-title":"Rituximab prolongs the time to relapse in patients with immune thrombotic thrombocytopenic purpura: analysis of off-label use in Japan.","volume":"112","author":"Kubo","year":"2020","journal-title":"Intern J Hematol."},{"key":"B122","doi-asserted-by":"publisher","first-page":"1076029618825309","DOI":"10.1177\/1076029618825309","article-title":"Comparison of the long-term remission of rituximab and conventional treatment for acquired thrombotic thrombocytopenic purpura: a systematic review and meta-analysis.","volume":"25","author":"Owattanapanich","year":"2019","journal-title":"Clin Appl Thrombosis\/Hemostasis."},{"key":"B123","doi-asserted-by":"publisher","first-page":"1746","DOI":"10.1182\/blood-2011-03-341131","article-title":"A phase 2 study of the safety and efficacy of rituximab with plasma exchange in acute acquired thrombotic thrombocytopenic purpura.","volume":"118","author":"Scully","year":"2011","journal-title":"Blood."},{"key":"B124","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.1182\/bloodadvances.2019031039","article-title":"Predictors of relapse and efficacy of rituximab in immune thrombotic thrombocytopenic purpura.","volume":"3","author":"Sun","year":"2019","journal-title":"Blood Adv."},{"key":"B125","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1111\/jth.12114","article-title":"Rituximab for thrombotic thrombocytopenic purpura: benefit of early administration during acute episodes and use of prophylaxis to prevent relapse.","volume":"11","author":"Westwood","year":"2013","journal-title":"J Thrombosis Haemostasis."},{"key":"B126","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1111\/j.1538-7836.2010.03818.x","article-title":"Rituximab pharmacokinetics during the management of acute idiopathic thrombotic thrombocytopenic purpura.","volume":"8","author":"McDonald","year":"2010","journal-title":"J Thrombosis Haemostasis."},{"key":"B127","doi-asserted-by":"publisher","first-page":"15","DOI":"10.2147\/JBM.S46458","article-title":"Management of thrombotic thrombocytopenic purpura: current perspectives.","volume":"5","author":"Blombery","year":"2014","journal-title":"J Blood Med."},{"key":"B128","doi-asserted-by":"publisher","first-page":"E26","DOI":"10.1002\/ajh.26022","article-title":"Efficacy of subcutaneous preemptive rituximab in immune-mediated thrombotic thrombocytopenic purpura: experience from the first 12 cases.","volume":"96","author":"Delrue","year":"2021","journal-title":"Am J Hematol."},{"key":"B129","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/s11239-018-1647-9","article-title":"Ofatumumab for acute treatment and prophylaxis of a patient with multiple relapses of acquired thrombotic thrombocytopenic purpura.","volume":"46","author":"Al-Samkari","year":"2018","journal-title":"J Thrombosis Thrombolysis."},{"key":"B130","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1111\/bjh.18192","article-title":"The use of obinutuzumab and ofatumumab in the treatment of immune thrombotic thrombocytopenic purpura.","volume":"198","author":"Doyle","year":"2022","journal-title":"Br J Haematol."},{"key":"B131","doi-asserted-by":"publisher","first-page":"E259","DOI":"10.1002\/ajh.25583","article-title":"Obinutuzumab in two patients suffering from immune-mediated thrombotic thrombocytopenic purpura intolerant to rituximab.","volume":"94","author":"Robertz","year":"2019","journal-title":"Am J Hematol."},{"key":"B132","doi-asserted-by":"publisher","first-page":"2436","DOI":"10.1111\/j.1537-2995.2012.03578.x","article-title":"Splenectomy and\/or cyclophosphamide as salvage therapies in thrombotic thrombocytopenic purpura: the French TMA Reference Center experience.","volume":"52","author":"Beloncle","year":"2012","journal-title":"Transfusion."},{"key":"B133","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1111\/j.1600-0609.1994.tb00649.x","article-title":"Vincristine sulfate for the treatment of thrombotic thrombocytopenic purpura refractory to plasma-exchange.","volume":"52","author":"Bobbio-Pallavicini","year":"1994","journal-title":"Eur J Haematol."},{"key":"B134","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/s00277-001-0395-6","article-title":"Vincristine as treatment for recurrent episodes of thrombotic thrombocytopenic purpura.","volume":"81","author":"Ferrara","year":"2002","journal-title":"Ann Hematol."},{"key":"B135","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1111\/j.1537-2995.2005.03146.x","article-title":"Combination vincristine and plasma exchange as initial therapy in patients with thrombotic thrombocytopenic purpura: one institution\u2019s experience and review of the literature.","volume":"45","author":"Ziman","year":"2005","journal-title":"Transfusion."},{"key":"B136","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1111\/j.1365-2141.2007.06819.x","article-title":"Ciclosporin and plasma exchange in thrombotic thrombocytopenic purpura: long-term follow-up with serial analysis of ADAMTS13 activity.","volume":"139","author":"Cataland","year":"2007","journal-title":"Br J Haematol."},{"key":"B137","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1111\/j.1537-2995.2012.03944.x","article-title":"Cyclosporin A therapy on idiopathic thrombotic thrombocytopenic purpura in the relapse setting: two case reports and a review of the literature.","volume":"53","author":"Yilmaz","year":"2013","journal-title":"Transfusion."},{"key":"B138","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1111\/j.1600-0609.2007.00832.x","article-title":"Mycophenolate mofetil in a case of relapsed, refractory thrombotic thrombocytopenic purpura.","volume":"78","author":"Ahmad","year":"2007","journal-title":"Eur J Haematol."},{"key":"B139","doi-asserted-by":"publisher","first-page":"3432","DOI":"10.1182\/bloodadvances.2019000575","article-title":"Thrombotic thrombocytopenic purpura and defective apoptosis due to CASP8\/10 mutations: the role of mycophenolate mofetil.","volume":"3","author":"Fioredda","year":"2019","journal-title":"Blood Adv."},{"key":"B140","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1016\/j.jtha.2024.10.034","article-title":"Bortezomib for rituximab-refractory immune-mediated thrombotic thrombocytopenic purpura in the caplacizumab era: an Italian multicenter study.","volume":"23","author":"Giannotta","year":"2025","journal-title":"J Thrombosis Haemostasis."},{"key":"B141","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1111\/bjh.13993","article-title":"Bortezomib in the treatment of refractory thrombotic thrombocytopenic purpura.","volume":"173","author":"Patriquin","year":"2016","journal-title":"Br J Haematol."},{"key":"B142","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1111\/bjh.18430","article-title":"Bortezomib, a promising alternative for patients with refractory or relapsed thrombotic thrombocytopenic purpura after rituximab treatment.","volume":"199","author":"Yin","year":"2022","journal-title":"Br J Haematol."},{"key":"B143","doi-asserted-by":"publisher","first-page":"4883","DOI":"10.1182\/blood-2025-4883","article-title":"Daratumumab for immune-mediated thrombotic thrombocytopenic purpura (iTTP): results from the international, multicenter darttp study.","volume":"146","author":"Giannotta","year":"2025","journal-title":"Blood."},{"key":"B144","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1182\/bloodadvances.2021005124","article-title":"Daratumumab for immune thrombotic thrombocytopenic purpura.","volume":"6","author":"van den Berg","year":"2022","journal-title":"Blood Adv."},{"key":"B145","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1358\/dot.2019.55.6.2989843","article-title":"Caplacizumab to treat immune-mediated thrombotic thrombocytopenic purpura.","volume":"55","author":"Poullin","year":"2019","journal-title":"Drugs Today."},{"key":"B146","doi-asserted-by":"publisher","first-page":"2132","DOI":"10.1182\/bloodadvances.2022008443","article-title":"Adding caplacizumab to standard of care in thrombotic thrombocytopenic purpura: a systematic review and meta-analysis.","volume":"7","author":"Djulbegovic","year":"2023","journal-title":"Blood Adv."},{"key":"B147","doi-asserted-by":"publisher","first-page":"3093","DOI":"10.1182\/bloodadvances.2020001987","article-title":"ADAMTS13 and VWF activities guide individualized caplacizumab treatment in patients with aTTP.","volume":"4","author":"V\u00f6lker","year":"2020","journal-title":"Blood Adv."},{"key":"B148","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1002\/rth2.12160","article-title":"Thrombotic thrombocytopenic purpura: toward targeted therapy and precision medicine.","volume":"3","author":"Coppo","year":"2019","journal-title":"Res Pract Thrombosis Haemostasis."},{"key":"B149","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1182\/blood.2019000954","article-title":"How targeted therapy disrupts the treatment paradigm for acquired TTP: the risks, benefits, and unknowns.","volume":"134","author":"Mazepa","year":"2019","journal-title":"Blood."},{"key":"B150","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/j.jtha.2022.11.010","article-title":"Impact of first-line use of caplacizumab on treatment outcomes in immune thrombotic thrombocytopenic purpura.","volume":"21","author":"V\u00f6lker","year":"2023","journal-title":"J Thrombosis Haemostasis."},{"key":"B151","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1111\/jth.15637","article-title":"Alternate-day dosing of caplacizumab for immune-mediated thrombotic thrombocytopenic purpura.","volume":"20","author":"K\u00fchne","year":"2022","journal-title":"J Thrombosis Haemostasis."},{"key":"B152","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1056\/NEJMc1905426","article-title":"Caplacizumab therapy without plasma exchange for acquired thrombotic thrombocytopenic purpura.","volume":"381","author":"Chander","year":"2019","journal-title":"New Engl J Med."},{"key":"B153","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1182\/blood.2023023780","article-title":"Management of immune thrombotic thrombocytopenic purpura without therapeutic plasma exchange.","volume":"144","author":"K\u00fchne","year":"2024","journal-title":"Blood."},{"key":"B154","doi-asserted-by":"publisher","first-page":"3061","DOI":"10.1111\/jth.15045","article-title":"Treatment of acquired thrombotic thrombocytopenic purpura without plasma exchange in selected patients under caplacizumab.","volume":"18","author":"V\u00f6lker","year":"2020","journal-title":"J Thrombosis Haemostasis."},{"key":"B155","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1007\/s12185-016-2019-x","article-title":"Efficacy and safety of rituximab in Japanese patients with acquired thrombotic thrombocytopenic purpura refractory to conventional therapy.","volume":"104","author":"Miyakawa","year":"2016","journal-title":"Intern J Hematol."},{"key":"B156","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1111\/jth.13571","article-title":"Consensus on the standardization of terminology in thrombotic thrombocytopenic purpura and related thrombotic microangiopathies.","volume":"15","author":"Scully","year":"2017","journal-title":"J Thrombosis Haemostasis."},{"key":"B157","doi-asserted-by":"publisher","first-page":"6219","DOI":"10.1182\/bloodadvances.2022008028","article-title":"Real-world effectiveness of caplacizumab vs the standard of care in immune thrombotic thrombocytopenic purpura.","volume":"6","author":"Izquierdo","year":"2022","journal-title":"Blood Adv."},{"key":"B158","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1097\/CCM.0b013e31822e9d66","article-title":"Efficacy and safety of first-line rituximab in severe, acquired thrombotic thrombocytopenic purpura with a suboptimal response to plasma exchange. Experience of the French thrombotic microangiopathies reference center.","volume":"40","author":"Froissart","year":"2012","journal-title":"Crit Care Med."},{"key":"B159","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1007\/s40271-019-00365-y","article-title":"Patient experience with congenital (Hereditary) thrombotic thrombocytopenic purpura: a conceptual framework of symptoms and impacts.","volume":"12","author":"Oladapo","year":"2019","journal-title":"Patient - Patient-Centered Outcomes Res."},{"key":"B160","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1056\/NEJMoa2314793","article-title":"Recombinant ADAMTS13 in congenital thrombotic thrombocytopenic purpura.","volume":"390","author":"Scully","year":"2024","journal-title":"New Engl J Med."},{"key":"B161","doi-asserted-by":"publisher","first-page":"103270","DOI":"10.1016\/j.rpth.2025.103270","article-title":"Optimizing the management of congenital thrombotic thrombocytopenic purpura.","volume":"9","author":"Glasner","year":"2025","journal-title":"Res Pract Thrombosis Haemostasis."},{"key":"B162","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1182\/bloodadvances.2023011972","article-title":"Management and follow-up of pregnancy-onset thrombotic thrombocytopenic purpura: the French experience.","volume":"8","author":"B\u00e9ranger","year":"2024","journal-title":"Blood Adv."},{"key":"B163","doi-asserted-by":"publisher","first-page":"1674","DOI":"10.1182\/blood-2013-11-538900","article-title":"Pregnancy outcomes following recovery from acquired thrombotic thrombocytopenic purpura.","volume":"123","author":"Jiang","year":"2014","journal-title":"Blood."},{"key":"B164","doi-asserted-by":"publisher","first-page":"e453","DOI":"10.1212\/NXI.0000000000000453","article-title":"Rituximab before and during pregnancy.","volume":"5","author":"Das","year":"2018","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"B165","doi-asserted-by":"publisher","first-page":"e30","DOI":"10.1111\/bjh.17833","article-title":"First use of the anti-VWF nanobody caplacizumab to treat iTTP in pregnancy.","volume":"196","author":"K\u00fchne","year":"2022","journal-title":"Br J Haematol."},{"key":"B166","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1111\/bjh.18888","article-title":"A safe and effective use of caplacizumab in pregnancy-related acquired thrombotic thrombocytopenic purpura.","volume":"202","author":"Odetola","year":"2023","journal-title":"Br J Haematol."},{"key":"B167","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1111\/bjh.19723","article-title":"TTP and pregnancy.","volume":"205","author":"Gounder","year":"2024","journal-title":"Br J Haematol."},{"key":"B168","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1016\/j.jtha.2025.10.012","article-title":"Successful use of recombinant ADAMTS13 in a pregnant patient with immune-mediated thrombotic thrombocytopenic purpura.","volume":"24","author":"Cauchois","year":"2026","journal-title":"J Thrombosis Haemostasis."},{"key":"B169","doi-asserted-by":"publisher","first-page":"102687","DOI":"10.1016\/j.rpth.2025.102687","article-title":"Prophylactic use of recombinant ADAMTS-13 during pregnancy for congenital thrombotic thrombocytopenic purpura.","volume":"9","author":"Colliou","year":"2025","journal-title":"Res Pract Thrombosis Haemostasis."},{"key":"B170","doi-asserted-by":"publisher","first-page":"100101","DOI":"10.1016\/j.bvth.2025.100101","article-title":"Recombinant ADAMTS-13 for congenital and immune thrombotic thrombocytopenic purpura in pregnancy.","volume":"2","author":"Howells","year":"2025","journal-title":"Blood Vessels Thrombosis Hemostasis."},{"key":"B171","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1515\/jpm-2024-0527","article-title":"Thrombotic thrombocytopenic purpura in pregnancy: a comprehensive review.","volume":"53","author":"Alsulmi","year":"2025","journal-title":"J Perinatal Med."},{"key":"B172","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.3390\/biomedicines13051038","article-title":"Thrombotic thrombocytopenic purpura in pediatric patients.","volume":"13","author":"Shrestha","year":"2025","journal-title":"Biomedicines."},{"key":"B173","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1182\/hematology.2025000759","article-title":"Modern management of congenital thrombotic thrombocytopenic purpura (cTTP).","volume":"2025","author":"Taylor","year":"2025","journal-title":"Hematology."},{"key":"B174","doi-asserted-by":"publisher","first-page":"4563","DOI":"10.1182\/bloodadvances.2024013488","article-title":"Caplacizumab in pediatric immune thrombotic thrombocytopenic purpura: the UK TTP Registry experience.","volume":"8","author":"Taylor","year":"2024","journal-title":"Blood Adv."},{"key":"B175","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1002\/jcph.1991","article-title":"Caplacizumab model-based dosing recommendations in pediatric patients with acquired thrombotic thrombocytopenic purpura.","volume":"62","author":"Bergstrand","year":"2022","journal-title":"J Clin Pharmacol."},{"key":"B176","doi-asserted-by":"publisher","first-page":"11346","DOI":"10.1182\/blood-2022-170608","article-title":"Plasmic (PLASMICkid) score for pediatric thrombotic thrombocytopenic purpura.","volume":"140","author":"Rairikar","year":"2022","journal-title":"Blood."},{"key":"B177","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1182\/blood.2019000748","article-title":"Immune thrombotic thrombocytopenic purpura in older patients: prognosis and long-term survival.","volume":"134","author":"Prevel","year":"2019","journal-title":"Blood."},{"key":"B178","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1097\/MD.0b013e3182603598","article-title":"Cancer-Related microangiopathic hemolytic anemia.","volume":"91","author":"Lechner","year":"2012","journal-title":"Medicine."},{"key":"B179","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1200\/JOP.2016.012096","article-title":"Microangiopathic hemolytic anemia and thrombocytopenia in patients with cancer.","volume":"12","author":"Morton","year":"2016","journal-title":"J Oncol Pract."},{"key":"B180","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1111\/hiv.13305","article-title":"HIV-associated thrombotic thrombocytopenic purpura (HIV-TTP): a practical guide and review of the literature.","volume":"23","author":"Louw","year":"2022","journal-title":"HIV Med."},{"key":"B181","doi-asserted-by":"publisher","first-page":"223","DOI":"10.3109\/10623320009072210","article-title":"The effects of HIV infection on endothelial function.","volume":"7","author":"Chi","year":"2000","journal-title":"Endothelium."},{"key":"B182","doi-asserted-by":"publisher","first-page":"ofz303","DOI":"10.1093\/ofid\/ofz303","article-title":"Good fences make good neighbors: human immunodeficiency virus and vascular disease.","volume":"6","author":"Mayne","year":"2019","journal-title":"Open Forum Infect Dis."},{"key":"B183","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1097\/QAD.0000000000002504","article-title":"Thrombotic thrombocytopenic purpura associated with AIDS: challenges in diagnosis and management.","volume":"34","author":"Yadava","year":"2020","journal-title":"AIDS."},{"key":"B184","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1111\/j.1365-2141.2011.08636.x","article-title":"Human immunodeficiency virus associated thrombotic thrombocytopenic purpura \u2013 favourable outcome with plasma exchange and prompt initiation of highly active antiretroviral therapy.","volume":"153","author":"Hart","year":"2011","journal-title":"Br J Haematol."},{"key":"B185","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1111\/j.1365-3083.2008.02143.x","article-title":"Human immunodeficiency virus-associated thrombotic microangiopathies: clinical characteristics and outcome according to ADAMTS13 activity.","volume":"68","author":"Malak","year":"2008","journal-title":"Scand J Immunol."},{"key":"B186","doi-asserted-by":"publisher","first-page":"89","DOI":"10.17925\/EOH.2012.08.02.89","article-title":"HIV-associated thrombotic thrombocytopenic purpura \u2014 what we know so far.","volume":"8","author":"Meiring","year":"2012","journal-title":"Eur Oncol Haematol."},{"key":"B187","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1111\/j.1365-2141.2004.05325.x","article-title":"Thrombotic thrombocytopenic purpura in patients with retroviral infection is highly responsive to plasma infusion therapy.","volume":"128","author":"Novitzky","year":"2005","journal-title":"Br J Haematol."},{"key":"B188","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1093\/cid\/ciu094","article-title":"Prevention and treatment of opportunistic infections in HIV-Infected adults and adolescents: updated guidelines from the centers for disease control and prevention, national institutes of health, and HIV medicine association of the infectious diseases Society of America.","volume":"58","author":"Masur","year":"2014","journal-title":"Clin Infect Dis."},{"key":"B189","doi-asserted-by":"publisher","first-page":"2337","DOI":"10.1016\/j.ekir.2024.04.043","article-title":"Infectious disease prophylaxis during and after immunosuppressive therapy.","volume":"9","author":"Schweitzer","year":"2024","journal-title":"Kidney Intern Rep."},{"key":"B190","doi-asserted-by":"publisher","first-page":"gfaa142.0240","DOI":"10.1093\/ndt\/gfaa142.P0240","article-title":"P0240 Acquired thrombotic thrombocytopenic purpura in HIV positive patients successfully treated with caplacizumab: about two cases.","volume":"35","author":"Baes","year":"2020","journal-title":"Nephrol Dial Trans."},{"key":"B191","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1002\/jca.21692","article-title":"HIV-associated thrombotic thrombocytopaenic purpura: a retrospective cohort study during the anti-retroviral therapy era.","volume":"34","author":"Masoet","year":"2019","journal-title":"J Clin Apher."},{"key":"B192","doi-asserted-by":"publisher","first-page":"40","DOI":"10.7196\/SAMJ.2019.v109i8b.13829","article-title":"HIV and haematopoiesis.","volume":"109","author":"Durandt","year":"2019","journal-title":"South Afr Med J."},{"key":"B193","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1182\/bloodadvances.2023010807","article-title":"A descriptive analysis of fatal outcomes in immune thrombotic thrombocytopenic purpura in the USTMA TTP Registry.","volume":"8","author":"Abou-Ismail","year":"2024","journal-title":"Blood Adv."},{"key":"B194","doi-asserted-by":"publisher","first-page":"1016.e1","DOI":"10.1016\/j.amjmed.2013.03.021","article-title":"Predictors of in-hospital mortality and acute myocardial infarction in thrombotic thrombocytopenic purpura.","volume":"126","author":"Balasubramaniyam","year":"2013","journal-title":"Am J Med."},{"key":"B195","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.3324\/haematol.2011.049676","article-title":"Development and validation of a predictive model for death in acquired severe ADAMTS13 deficiency-associated idiopathic thrombotic thrombocytopenic purpura: the French TMA Reference Center experience.","volume":"97","author":"Benhamou","year":"2012","journal-title":"Haematologica."},{"key":"B196","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1182\/blood-2016-12-758656","article-title":"Presenting ADAMTS13 antibody and antigen levels predict prognosis in immune-mediated thrombotic thrombocytopenic purpura.","volume":"130","author":"Alwan","year":"2017","journal-title":"Blood."},{"key":"B197","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1182\/bloodadvances.2020004169","article-title":"Cardiovascular disease is a leading cause of mortality among TTP survivors in clinical remission.","volume":"6","author":"Sukumar","year":"2022","journal-title":"Blood Adv."},{"key":"B198","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1182\/blood.2019001056","article-title":"Reduced ADAMTS13 activity during TTP remission is associated with stroke in TTP survivors.","volume":"134","author":"Upreti","year":"2019","journal-title":"Blood."},{"key":"B199","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1182\/blood-2009-09-243790","article-title":"Survival and relapse in patients with thrombotic thrombocytopenic purpura.","volume":"115","author":"Kremer Hovinga","year":"2010","journal-title":"Blood."},{"key":"B200","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1182\/blood.2021014514","article-title":"How I treat immune-mediated thrombotic thrombocytopenic purpura after hospital discharge.","volume":"140","author":"Akwaa","year":"2022","journal-title":"Blood."},{"key":"B201","doi-asserted-by":"publisher","first-page":"5091","DOI":"10.1182\/bloodadvances.2023010028","article-title":"A novel von Willebrand factor multimer ratio as marker of disease activity in thrombotic thrombocytopenic purpura.","volume":"7","author":"Falter","year":"2023","journal-title":"Blood Adv."},{"key":"B202","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1182\/hematology.2025000758","article-title":"Challenges and opportunities in the long-term management of immune-mediated TTP.","volume":"2025","author":"Boothby","year":"2025","journal-title":"Hematology."},{"key":"B203","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.1016\/S0140-6736(23)01460-5","article-title":"Efficacy and safety of the neonatal Fc receptor inhibitor efgartigimod in adults with primary immune thrombocytopenia (ADVANCE IV): a multicentre, randomised, placebo-controlled, phase 3 trial.","volume":"402","author":"Broome","year":"2023","journal-title":"Lancet."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1806030\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T16:05:19Z","timestamp":1789488319000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1806030\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,15]]},"references-count":203,"alternative-id":["10.3389\/fmed.2026.1806030"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1806030","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,15]]},"article-number":"1806030"}}